201 related articles for article (PubMed ID: 34464000)
1. PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1-34.
Ovejero D; Hartley IR; de Castro Diaz LF; Theng E; Li X; Gafni RI; Collins MT
J Bone Miner Res; 2022 Feb; 37(2):179-184. PubMed ID: 34464000
[TBL] [Abstract][Full Text] [Related]
2. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Ito N; Fukumoto S
Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
[TBL] [Abstract][Full Text] [Related]
3. Use of Teriparatide in Hyperphosphatemic Familial Tumor Calcinosis: Evaluating the Interaction Between FGF23 and PTH on the Phosphaturic Effect.
Pallone SG; Kunii IS; da Silva REC; Lazaretti-Castro M
Calcif Tissue Int; 2022 Jul; 111(1):102-106. PubMed ID: 35338393
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G; Price HE; Shore RM; White KE; Langman CB
Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
[TBL] [Abstract][Full Text] [Related]
5. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
[TBL] [Abstract][Full Text] [Related]
6. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ; Imel EA
Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
[TBL] [Abstract][Full Text] [Related]
9. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
[TBL] [Abstract][Full Text] [Related]
11. Fgf23 and parathyroid hormone signaling interact in kidney and bone.
Andrukhova O; Streicher C; Zeitz U; Erben RG
Mol Cell Endocrinol; 2016 Nov; 436():224-39. PubMed ID: 27498418
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
[TBL] [Abstract][Full Text] [Related]
13. In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules.
Ide N; Ye R; Courbebaisse M; Olauson H; Densmore MJ; Larsson TE; Hanai JI; Lanske B
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1261-F1270. PubMed ID: 29993278
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
Yamashita H; Yamazaki Y; Hasegawa H; Yamashita T; Fukumoto S; Shigematsu T; Kazama JJ; Fukagawa M; Noguchi S
Endocr J; 2007 Jun; 54(3):465-70. PubMed ID: 17464094
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
Boyce AM; Lee AE; Roszko KL; Gafni RI
Front Endocrinol (Lausanne); 2020; 11():293. PubMed ID: 32457699
[TBL] [Abstract][Full Text] [Related]
18. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
[TBL] [Abstract][Full Text] [Related]
19. [Disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2010 Mar; 58(3):225-31. PubMed ID: 20408440
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]